Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -93.03% | 433.79% | 509.48% | -87.03% | 5,910.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.03% | 433.79% | 509.48% | -87.03% | 5,910.39% |
| Cost of Revenue | 38.15% | 16.93% | 56.71% | 45.91% | 77.01% |
| Gross Profit | -145.57% | 73.59% | 71.55% | -105.74% | 499.39% |
| SG&A Expenses | -12.19% | -1.09% | 22.39% | -4.66% | 21.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.83% | 12.57% | 47.31% | 29.36% | 56.42% |
| Operating Income | -170.84% | 53.30% | 40.91% | -113.17% | 320.10% |
| Income Before Tax | -159.25% | 65.48% | 54.32% | -109.07% | 342.34% |
| Income Tax Expenses | -28.95% | 124.29% | -59.32% | -98.01% | 5,037.50% |
| Earnings from Continuing Operations | -161.15% | 65.08% | 54.34% | -109.13% | 338.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.15% | 65.08% | 54.34% | -109.13% | 338.70% |
| EBIT | -170.84% | 53.30% | 40.91% | -113.17% | 320.10% |
| EBITDA | -167.31% | 55.72% | 43.99% | -112.09% | 333.46% |
| EPS Basic | -146.40% | 73.53% | 65.57% | -106.50% | 309.20% |
| Normalized Basic EPS | -144.96% | 73.84% | 65.58% | -106.45% | 312.60% |
| EPS Diluted | -147.68% | 72.90% | 64.73% | -106.80% | 302.93% |
| Normalized Diluted EPS | -146.07% | 73.84% | 65.58% | -106.69% | 307.45% |
| Average Basic Shares Outstanding | 31.81% | 31.89% | 32.63% | 40.57% | 14.10% |
| Average Diluted Shares Outstanding | 28.61% | 31.89% | 32.63% | 35.47% | 16.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |